Team:UB Indonesia/backup

From 2014.igem.org

(Difference between revisions)
 
(12 intermediate revisions not shown)
Line 132: Line 132:
                                         <div id="preventing" style="display:none;width:700px;">
                                         <div id="preventing" style="display:none;width:700px;">
<h2><center>“Prevent is Better than Cure”</center></h2>
<h2><center>“Prevent is Better than Cure”</center></h2>
-
<p align="justify">Indonesia is an agricultural country that most of their society works as farmer. One of commodity in Indonesia is tea plantation which is located in Malang (Brawijaya University takes place). Malang is resited at 440-667 (mdpl) altitude, one of the tourist destinations in East Java because of the potential of natural and climatic owned. Malang climate conditions during 2008 temperatures recorded ranging from 22.7 ° C to 25.1 ° C. While the maximum temperature reached 32.7 ° C and minimum temperature of 18.4 ° C. The average air humidity range 79% - 86%. With a maximum moisture content of 99% and a minimum at 40%. These conditions favor the development of the tea plant (Camellia sinensis). <br><br>
+
<p align="justify">Indonesia is an agricultural country that most of their society works as farmer. One of commodity in Indonesia is tea plantation which is located in Malang (Brawijaya University takes place). Malang is resited at 440-667 (mdpl) altitude, one of the tourist destinations in East Java because of the potential of natural and climatic owned. Malang climate conditions during 2008 temperatures recorded ranging from 22.7 ° C to 25.1 ° C. While the maximum temperature reached 32.7 ° C and minimum temperature of 18.4 ° C. The average air humidity range 79% - 86%. With a maximum moisture content of 99% and a minimum at 40%. These conditions favor the development of the tea plant (Camellia sinensis). <br>
-
<center><img src="https://static.igem.org/mediawiki/2014/e/ed/UB-Tea.PNG" width="" height=""></center>
+
<center><img src="https://static.igem.org/mediawiki/2014/e/ed/UB-Tea.PNG" width="" height=""></center><br>
Tea extract contain EGCG used as the most effective antioxidant to against cervical cancer. But, levels of EGCG (Epigallocathecin gallate) in tea is very slightly. So, we will increase the level of this EGCG compound using siRNA to knockdown gene non-EGCG with expectation it will produce high yield of antioxidant. The applications are for supplement or feminine hygiene.<br><br>
Tea extract contain EGCG used as the most effective antioxidant to against cervical cancer. But, levels of EGCG (Epigallocathecin gallate) in tea is very slightly. So, we will increase the level of this EGCG compound using siRNA to knockdown gene non-EGCG with expectation it will produce high yield of antioxidant. The applications are for supplement or feminine hygiene.<br><br>
Line 369: Line 369:
</ul>
</ul>
<br><br>
<br><br>
-
<li>Screening</li>
+
<li><b>SCREENING</b></li>
 +
<p align="justify"><b>April – May</b><br>
 +
We found some literatures for our Screening Project and combine some projects from previous team. We decided to use Golden Gate Assembly from <a href="https://2012.igem.org/Team:Freiburg">Freiburg team 2012</a> to synthesis our TALE. Our screening kit is related to <a href="https://2013.igem.org/Team:Calgary">Calgary team 2013</a> model but we use AmylCP reporter from <a href="https://2011.igem.org/Team:Uppsala-Sweden">UPPSALA team 2011</a>. <br>
 +
<b>June-July</b><br>
 +
The TALE and AmylCP will be linked by E coil and K coil that created by  <a href="https://2013.igem.org/Team:Calgary">Calgary team 2013</a>, so we ordered them from IGEM. The bio bricks stocks is limited so we have to clone them, we transformed them to E. coli competent cell. In the beginning we use local strain E. coli but the cells has low efficiency.</p><br>
 +
<center><img src="https://static.igem.org/mediawiki/2014/9/95/UB-Lab-journal.jpg" width="500px" height="200"><br>
 +
Figure 1. <a href="http://parts.igem.org/Part:BBa_J04450">BBa_J04450</a> not inserted to local E. coli competent cell bacteria.</center><br><br>
 +
<p align="center">
 +
<b>August</b><br>
 +
We made DH5-α competent cell bacteria and test the efficiency with tansform our parts. First trial we succeded to transform our TALE direpeat parts from kit plate 2. We run the isolated plasmid into agarose gel before and after PCR.<br>
 +
</p>
 +
<center><img src="https://static.igem.org/mediawiki/2014/c/c7/UB-lab_journal2.jpg" width="500px" height="200"><br>
 +
Figure 2. The bio bricks were transformed into the new competent cell (DH5-α). Size of the parts are about 2200bp shown in the yellow box. <br><br>
 +
<img src="https://static.igem.org/mediawiki/2014/6/60/UB-lab_journal3.jpg" width="500px" height="200"><br>
 +
Figure 3. PCR products after we inserted the parts into DH5-α competent cell. The control band are shown in the K1 and K2 line that related to there is no problem with PCR technique. Only 4I part that successfully amplified.</center><br><br>
 +
<p align="justify">
 +
<b>September - October</b><br>
 +
These months we tried to synthesize our TALEs after clone the parts, but still there are 2 parts that not amplified yet (6A and 12E). We don’t have BsmBI restriction enzyme to Golden Gate Assembly but we found that EcoRI has the same restriction site as BsmBI. We substituted the BsmBI with EcoRI and  the parts successfully inserted into pSB1C3 (3200 bp).</p><br>
 +
<center><img src="https://static.igem.org/mediawiki/2014/c/c4/UB-lab_journal4.jpg" width="500px" height="200"><br>
 +
Figure 4. There are two TALES we tried to synthesize, TALE 1 and TALE 2. Every TALE has triplo but only T1-2, T2-1, and T2-2 succesfully assembled.</center><br>
 +
<p align="justify">
 +
We collected as many as possible references for the application content. Our application is android mobile based and we started to encode it. The application consist of preventing and therapy suggestion also screening method information. Special feature from our application is snap tool that can detect the kit result.
 +
</p>
</ul>
</ul>
</p>
</p>
Line 541: Line 563:
</p>
</p>
<center>
<center>
-
<table><tr><th>Component</th><th>Amount (μl)</th></tr>
+
<table border="1">
 +
<tr><th>Component</th><th>Amount (μl)</th></tr>
<tr><td>6 di-repeat plasmids (60ng)<br>
<tr><td>6 di-repeat plasmids (60ng)<br>
Expression vector (170ng)<br>
Expression vector (170ng)<br>
Line 560: Line 583:
</td></tr>
</td></tr>
<tr><td>Total</td><td>20</td></tr>
<tr><td>Total</td><td>20</td></tr>
 +
</table><br><br>
 +
<b>PCR Cycle</b><br>
 +
<table border="1">
 +
<tr><th>Cycle</th><th>Temperature and time</th></tr>
 +
<tr><td>1-13</td><td>37 °C, 5 minutes </td></tr>
 +
<tr><td></td><td>20 °C, 5 minutes </td></tr>
 +
<tr><td>14</td><td>50 °C, 10 minutes </td></tr>
 +
<tr><td>15</td><td>80 °C, 10 minutes </td></tr>
</table>
</table>
-
</center>
+
</center><br><br>
 +
4. Transform the products into a competent E. coli, such as DH10B and Top10. Note that selection of the right clones will not be successful with ccdB-resistant E.coli strains. <br>
 +
Add 5 μl of the ligation product to 50 μl of competent bacteria, incubate on ice for 30 min, perform heat shock at 42 °C for 1 minute, then incubate on ice for 5 minutes. Add 500 μl of pre-warmed LB medium, incubate at 37 °C for 1 h on a shaking thermo block, plate on an agar plate containing chlorampenicol and incubate at 37°C overnight.<br>
 +
5. Put a single colony on a new LB agar plate with chlorampenicol and Incubate for 16 hours.<br>
 +
6. If the repeat array already in the expression plasmid, then transfecting into cells.<br>
 +
7. Perform electrophoresis in order to check the successfull of TALE assembly.<br>
 +
 
 +
 
 +
 
                                         </div>
                                         </div>
<h2 class="font-thin"><font color="#fff">Protocols</font></h2>
<h2 class="font-thin"><font color="#fff">Protocols</font></h2>
Line 694: Line 733:
We upgraded the standard biobrick backbone pSB1C3 with added by promotor sequences of  p105 and GFP (E0240). This pSB1C3 has contained  chloramphenicol resistance. Our major achievements is to confirm that herbal compound can  react with promotor of HPV 16 and 18 in HeLa cells.  GFP give green colour to confirm whether herbal compound can attach and stop the HeLa cell activity transformed with p105 promotor sequence
We upgraded the standard biobrick backbone pSB1C3 with added by promotor sequences of  p105 and GFP (E0240). This pSB1C3 has contained  chloramphenicol resistance. Our major achievements is to confirm that herbal compound can  react with promotor of HPV 16 and 18 in HeLa cells.  GFP give green colour to confirm whether herbal compound can attach and stop the HeLa cell activity transformed with p105 promotor sequence
</p><br>
</p><br>
-
<center><img src="" width="" height=""></center>
+
<center><img src="https://static.igem.org/mediawiki/2014/f/f9/UB-BBa_E0240_-_P105_Map.png" width="500px" height="400"></center>
<p align="justify">
<p align="justify">
Line 700: Line 739:
Standard biobrick backbone pSB1C3 containing chloramphenicol resistance.  The backbone added  by promotor sequences of  p97 and GFP (E0240).  GFP act as a marker that give green colour to confirm  whether herbal compound can attach  and stop the HeLa cell activity transformed with p97 promotor sequence.
Standard biobrick backbone pSB1C3 containing chloramphenicol resistance.  The backbone added  by promotor sequences of  p97 and GFP (E0240).  GFP act as a marker that give green colour to confirm  whether herbal compound can attach  and stop the HeLa cell activity transformed with p97 promotor sequence.
</p><br>
</p><br>
-
<center><img src="" width="" height=""></center>
+
<center><img src="https://static.igem.org/mediawiki/2014/1/15/UB-BBa_EO240_-_p97_Map.png" width="500px" height="400"></center>
 +
<br><br>
 +
<b>Preventing and Therapy Team Safety</b>
 +
<center><table border="1">
 +
<tr><th>Part Number</th><th>DNA Source</th><th>Species Origin</th><th>Species Risk Group</th><th>Part Function</th></tr>
 +
<tr><td>Bba_K747096</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>CMV Promoter</td></tr>
 +
<tr><td>Bba_E0240</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>GFP Generator</td></tr>
 +
<tr><td>Bba_K516132</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Constitutive promoter with mRFP, RBS B0032</td></tr>
 +
<tr><td>pTALEN</td><td>From BIOSS in University of Freiburg, Germany</td><td>Xanthomonas spp.</td><td>2</td><td>Vector</td></tr>
 +
<tr><td>pTAL-TF</td><td>From BIOSS in University of Freiburg, Germany</td><td>Xanthomonas spp.</td><td>2</td><td>Vector</td></tr>
 +
<tr><td>p97 promoter</td><td>Synthesized by IDT</td><td>HPV type 16</td><td>2</td><td>Cell Line</td></tr>
 +
<tr><td>p105 promoter</td><td>Synthesized by IDT</td><td>HPV type 16</td><td>2</td><td>Cell Line</td></tr>
 +
</table>
 +
<br><br>
 +
<table border="1">
 +
<tr><th>Part Number</th><th>DNA Source</th><th>Species Origin</th><th>Species Risk Group</th><th>Part Function</th></tr>
 +
<tr><td>Bba_K747012</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747016</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747042</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747048</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747064</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747091</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747012</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747026</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747036</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747052</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747076</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747095</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747101</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Plasmid </td></tr>
 +
 
 +
</table>
 +
</center>
                                         </div>
                                         </div>
<h2 class="font-thin"><font color="#fff">Submitted Parts</font></h2>
<h2 class="font-thin"><font color="#fff">Submitted Parts</font></h2>
Line 733: Line 803:
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="https://static.igem.org/mediawiki/2014/4/4d/UB-Advisor.JPG"><img class="thumb" src="https://static.igem.org/mediawiki/2014/4/4d/UB-Advisor.JPG" alt=""></a></div>
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="https://static.igem.org/mediawiki/2014/4/4d/UB-Advisor.JPG"><img class="thumb" src="https://static.igem.org/mediawiki/2014/4/4d/UB-Advisor.JPG" alt=""></a></div>
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="https://static.igem.org/mediawiki/2014/0/03/Foto_seminar_biologi_sintetikUB.jpg"><img class="thumb" src="https://static.igem.org/mediawiki/2014/0/03/Foto_seminar_biologi_sintetikUB.jpg" alt=""></a></div>
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="https://static.igem.org/mediawiki/2014/0/03/Foto_seminar_biologi_sintetikUB.jpg"><img class="thumb" src="https://static.igem.org/mediawiki/2014/0/03/Foto_seminar_biologi_sintetikUB.jpg" alt=""></a></div>
-
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="images/portfolio/p03-large.jpg"><img class="thumb" src="https://static.igem.org/mediawiki/2014/4/4b/Wiraeka.jpg" alt=""></a></div>
+
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="https://static.igem.org/mediawiki/2014/c/c0/UB-labwork4.JPG"><img class="thumb" src="https://static.igem.org/mediawiki/2014/c/c0/UB-labwork4.JPG" alt=""></a></div>
-
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="images/portfolio/p04-large.jpg"><img class="thumb" src="https://static.igem.org/mediawiki/2014/4/4b/Wiraeka.jpg" alt=""></a></div>
+
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="https://static.igem.org/mediawiki/2014/e/e0/UB-labwork1.JPG"><img class="thumb" src="https://static.igem.org/mediawiki/2014/e/e0/UB-labwork1.JPG" alt=""></a></div>
-
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="images/portfolio/p11-large.jpg"><img class="thumb" src="https://static.igem.org/mediawiki/2014/4/4b/Wiraeka.jpg" alt=""></a></div>
+
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="https://static.igem.org/mediawiki/2014/b/b0/UB-labwork2.JPG"><img class="thumb" src="https://static.igem.org/mediawiki/2014/b/b0/UB-labwork2.JPG" alt=""></a></div>
-
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="images/portfolio/p12-large.jpg"><img class="thumb" src="https://static.igem.org/mediawiki/2014/4/4b/Wiraeka.jpg" alt=""></a></div>
+
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="https://static.igem.org/mediawiki/2014/e/e4/UB_Go_Get_GOLD.jpg"><img class="thumb" src="https://static.igem.org/mediawiki/2014/e/e4/UB_Go_Get_GOLD.jpg" alt=""></a></div>
</div><!-- /row -->
</div><!-- /row -->
</div><!-- /slide3 -->
</div><!-- /slide3 -->
Line 868: Line 938:
</div><!-- /col12 -->
</div><!-- /col12 -->
<div class="col-12 col-lg-4 col-sm-6">
<div class="col-12 col-lg-4 col-sm-6">
-
<a href="#"><p><i class="icon icon-star"></i></p></a>
+
<a href="#sponsor" class="fancybox"><p><i class="icon icon-star"></i></p></a>
 +
                                        <div id="sponsor" style="display:none;width:700px;">
 +
                                        <center><img src="https://static.igem.org/mediawiki/2014/d/d6/UB-Sponsors.jpg" width="500" height="400"></center>
 +
                                        </div>
<h2 class="font-thin"><font color="#fff">Sponsors</font></h2>
<h2 class="font-thin"><font color="#fff">Sponsors</font></h2>
</div><!-- /col12 -->
</div><!-- /col12 -->

Latest revision as of 19:18, 16 October 2014

iGEM2014 | UB INDONESIA

BRAWIJAYA UNIVERSITY , INDONESIA

This is team wiki to share our iGEM experience



iGEM UB
BRAWIJAYA UNIVERSITY
iGEM2014
PROJECT
 
Abstract ...

Background

Overview

Preventing

Screening

Therapy

NOTEBOOK
 
Description

Timeline

Lab Journal

Detail.

Protocols

Detail.

HUMAN PRACTICE
 
Teks description

Workshop

Education

Society

COLLABORATIONS
 
Description

SYNBIO FOR INDONESIA

PARTS
 
Description

Submitted Parts

Favorite Parts

ABOUT US
 
Description

Members

Sponsors

Leave us a message
 
You can find us literally anywhere,

just push a button and we’re there

in/igemub

igemub@gmail.com

Malang, Indonesia
zip code 65145

facebook/igembrawijaya

@igem_ub